Respiri

Respiri is an ASX-listed company developing SaaS diagnostic solutions to support respiratory health management. Its technology detects wheeze, a typical symptom of asthma, chronic obstructive pulmonary disease and respiratory disease, to provide an objective measure of airway limitation.

Equities

Equities by Sector

Sectors

Thematics

Latest

Hybrid Air Vehicles – Redefining air travel and air freight

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Audiovisual

Latest

Mendus – equity proposition

The Law Debenture Corporation in 60 seconds

Team Internet – executive interview

About Edison

About Edison

Careers

Respiri (ASX: RSH)

Latest Insights

Respiri — Access platform-led growth prospects ahead

Respiri — Early onset of synergies from Access acquisition

Respiri — Raise anticipated to fund the Access acquisition

Respiri — wheezo to access a larger addressable market

Sector

Respiri — Trading recap highlights continued market traction

Respiri — NC rollout to expand wheezo market potential

Respiri — New funding to support commercial traction

Respiri — Sixth in spate of new client wins

Respiri — Shorter pilot study, potentially faster roll-out

Respiri — First primary care setting client win

Respiri — Commercialization efforts gathering steam

Respiri — Wheezo bags third client win in the US

Respiri — First patient enrolled in the US RPM programme

Respiri — Focus on cost optimisation

Respiri — Objective measures for better outcomes

Respiri – executive interview

Respiri — Wheezo to begin patient use in the US

Respiri — NIHR funding to seek better outcomes